References
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
- Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013;121:3703–3708.
- Go SI, Lee WS, Lee GW, et al. Nilotinib-induced interstitial lung disease. Int J Hematol 2013;98:361–365.
- Lin JT, Yeh KT, Fang HY, et al. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma 2006;47:1693–1695.
- Izumiyama N, Noguchi K, Takahashi H, et al. Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST). Nihon Kokyuki Gakkai Zasshi 2009;47:918–923.